TRCT
PRME icon

Tower Research Capital (TRC)’s Prime Medicine PRME Stock Holding History

Tower Research Capital (TRC)’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.9K Buy
21,814
+21,007
+2,603% +$80K ﹤0.01% 2395
2025
Q4 		$2.8K Sell
807
-3,085
-79% -$13.7K ﹤0.01% 4469
2025
Q3 		$21.6K Sell
3,892
-8,354
-68% -$33.9K ﹤0.01% 3251
2025
Q2 		$30.2K Buy
12,246
+2,337
+24% +$3.6K ﹤0.01% 3393
2025
Q1 		$19.7K Buy
9,909
+8,512
+609% +$21.7K ﹤0.01% 2985
2024
Q4 		$4.08K Sell
1,397
-6,652
-83% -$23.4K ﹤0.01% 4520
2024
Q3 		$31.1K Buy
8,049
+2,892
+56% +$13.4K ﹤0.01% 2978
2024
Q2 		$26.5K Sell
5,157
-1,906
-27% -$11.6K ﹤0.01% 3575
2024
Q1 		$49.4K Sell
7,063
-13,948
-66% -$106K ﹤0.01% 2285
2023
Q4 		$186K Buy
21,011
+17,483
+496% +$135K ﹤0.01% 2168
2023
Q3 		$33.7K Buy
3,528
+385
+12% +$5K ﹤0.01% 2920
2023
Q2 		$46K Sell
3,143
-82
-3% -$1.15K ﹤0.01% 2648
2023
Q1 		$40K Buy
3,225
+2,852
+765% +$46.5K ﹤0.01% 2716
2022
Q4 		$7K Buy
+373
New +$6.74K ﹤0.01% 4604

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Tower Research Capital (TRC)'s PRME Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Prime Medicine (PRME) stake by 2,603% in Q1 2026, buying an estimated $80K and bringing the position to 21,814 shares worth $75.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2395.

Tower Research Capital (TRC) first reported a position in PRME in Q4 2022 and has held it in 14 quarters since. The position peaked at $186K in Q4 2023. 192 funds tracked by Wall St. Rank hold PRME as of Q1 2026.

  • Tower Research Capital (TRC) held 21,814 shares of Prime Medicine worth $75.9K as of Q1 2026.
  • Tower Research Capital (TRC) bought 21,007 Prime Medicine shares in Q1 2026, an estimated $80K.
  • Prime Medicine made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #2395 holding.
  • Tower Research Capital (TRC) first reported a position in Prime Medicine in Q4 2022 and has held it in 14 quarters since.
  • Tower Research Capital (TRC)'s Prime Medicine position peaked at $186K in Q4 2023.
  • 192 funds tracked by Wall St. Rank held Prime Medicine as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.